Key takeaways for clinops professionals
- Inluriyo reduced risk of progression or death by 38% versus standard endocrine therapy in ESR1-mutated metastatic breast cancer.
- The oral administration provides a more convenient alternative to injectables, with a manageable safety profile and mostly Grade 1-2 adverse events.
- The ongoing EMBER-4 trial will determine Inluriyo’s role in the adjuvant setting, with implications for long-term recurrence prevention.
The FDA has approved Eli Lilly’s Inluriyo (imlunestrant) for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).1
EMBER-3 trial results
The approval is based on data from the ESR1-mutated MBC patient population in the Phase III EMBER-3 clinical trial (NCT04975308). In the study, Inluriyo reduced the risk of progression or death by 38% versus ET. Additionally, the oral estrogen receptor antagonist significantly improved progression-free survival (PFS) versus fulvestrant or exemestane, with a median PFS of 5.5 months versus 3.8 months.
In a press release, Jacob Van Naarden, executive vice president and president of Lilly Oncology, said: "This therapy reflects our commitment to developing treatments that improve outcomes for people with breast cancer and represents an important step toward advancing innovative, all-oral treatment approaches. We are deeply grateful to the patients, investigators, Lilly team members and clinical care teams who made this advancement possible. This therapy has the potential to make the treatment journey more manageable for those living with breast cancer."
Study design
EMBER-3 is randomized, open-label study in patients with ER+, HER2– locally advanced or metastatic breast cancer whose disease recurred or progressed after aromatase inhibitor therapy with or without a CDK4/6 inhibitor.
- The trial enrolled 874 adults, with 32% entering as first-line treatment for metastatic disease after the adjuvant setting and 64% as second-line treatment following progression on initial metastatic therapy.
- Patients were randomized to receive Inluriyo, investigator’s choice of fulvestrant or exemestane, or Inluriyo in combination with abemaciclib.2
In the press release, Komal Jhaveri, MD, FACP, FASCO, section head of Endocrine Therapy Research and clinical director of Early Drug Development at Memorial Sloan Kettering Cancer Center, and a principal investigator of EMBER-3, added: "This represents an important advancement for patients with ESR1-mutated MBC, a mutation found in nearly half of patients who have taken hormone therapies, often contributing to treatment resistance. With its demonstrated efficacy, tolerability profile and oral administration, this therapy provides a meaningful alternative treatment option for this patient population."